Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Nardana Bazybek, Yi Wei & Guanghui Ma. (2022) Advances in encapsulating gonadotropin-releasing hormone agonists for controlled release: a review. Journal of Microencapsulation 39:5, pages 452-466.
Read now
Read now
Axel S Merseburger & Marie Christine Roesch. (2022) Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer. Expert Review of Anticancer Therapy 22:7, pages 703-715.
Read now
Read now
M. Raschid Hoda, Mario W. Kramer, Axel S. Merseburger & Marcus V. Cronauer. (2017) Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opinion on Pharmacotherapy 18:1, pages 105-113.
Read now
Read now
Aaron Spitz, Marc Gittelman, Lawrence I Karsh, Sanja Dragnic, Ahmed M Soliman, Aditya Lele, Damian Gruca & Michael Norton. (2016) Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. Research and Reports in Urology 8, pages 159-164.
Read now
Read now
Articles from other publishers (14)
Kristof Chwalisz. (2023) Clinical development of the GnRH agonist leuprolide acetate depot. F&S Reports 4:2, pages 33-39.
Crossref
Crossref
Samer R. Abulateefeh. (2022) Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic. Drug Delivery and Translational Research 13:2, pages 520-530.
Crossref
Crossref
Yagmur Tasdemiroglu, Robert G. Gourdie & Jia-Qiang He. (2022) In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases. European Journal of Pharmacology 932, pages 175192.
Crossref
Crossref
Juan Morote, Adriana Aguilar, Jacques Planas & Enrique Trilla. (2022) Definition of Castrate Resistant Prostate Cancer: New Insights. Biomedicines 10:3, pages 689.
Crossref
Crossref
Wei Li, Jie Tang, Dennis Lee, Thomas R. Tice, Steven P. Schwendeman & Mark R. Prausnitz. (2022) Clinical translation of long-acting drug delivery formulations. Nature Reviews Materials 7:5, pages 406-420.
Crossref
Crossref
Ange B. Ilangala, Anna Lechanteur, Marianne Fillet & Géraldine Piel. (2021) Therapeutic peptides for chemotherapy: Trends and challenges for advanced delivery systems. European Journal of Pharmaceutics and Biopharmaceutics 167, pages 140-158.
Crossref
Crossref
Nazanin Momeni Roudsari, Naser-Aldin Lashgari, Saeideh Momtaz, Shaghayegh Abaft, Fatemeh Jamali, Pardis Safaiepour, Kiyana Narimisa, Gloria Jackson, Anusha Bishayee, Nima Rezaei, Amir Hossein Abdolghaffari & Anupam Bishayee. (2021) Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. Pharmaceutics 13:8, pages 1195.
Crossref
Crossref
Mian Fu, Xiaomei Zhuang, Tianhong Zhang, Ying Guan, Qingbin Meng & Yongjun Zhang. (2020) Hydrogen‐Bonded Films for Zero‐Order Release of Leuprolide. Macromolecular Bioscience 20:9, pages 2000050.
Crossref
Crossref
David RH Christie, Christopher F Sharpley, Natalia Mitina, Eamonn MacAteer, James E Jackson & Dominic Lunn. (2020) Is prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo‐adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration?. Journal of Medical Imaging and Radiation Oncology 64:2, pages 287-292.
Crossref
Crossref
Mian Fu, Xiaomei Zhuang, Tianhong Zhang, Ying Guan, Qingbin Meng & Yongjun Zhang. (2020) PEGylated leuprolide with improved pharmacokinetic properties. Bioorganic & Medicinal Chemistry 28:4, pages 115306.
Crossref
Crossref
E. David Crawford, Axel Heidenreich, Nathan Lawrentschuk, Bertrand Tombal, Antonio C. L. Pompeo, Arturo Mendoza-Valdes, Kurt Miller, Frans M. J. Debruyne & Laurence Klotz. (2018) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases 22:1, pages 24-38.
Crossref
Crossref
Sonja Cabarkapa, Marlon Perera, Ken Sikaris, Jonathan S. O’Brien, Damien M. Bolton & Nathan Lawrentschuk. (2018) Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?. Prostate International 6:1, pages 1-6.
Crossref
Crossref
Davide Meani, Mladen Solarić, Harri Visapää, Rose-Marie Rosén, Robert Janknegt & Majana Soče. (2017) Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care. Therapeutic Advances in Urology 10:2, pages 51-63.
Crossref
Crossref
Mladen Solarić, Anders Bjartell, Ursula Thyroff-Friesinger & Davide Meani. (2017) Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation. Therapeutic Advances in Urology 9:6, pages 127-136.
Crossref
Crossref